EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer

Chunfang Hao, Yunchu Wei, Wenjing Meng, Jie Zhang, Xiaonan Yang

Cancer Treatment Reviews · 2025-01 · 132 · 102861

DOI: 10.1016/j.ctrv.2024.102861 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2025-01. Verfasst von Chunfang Hao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Tianjin Cancer Hospital Airport Hospital, Tianjin, China; National Clinical…. Hauptthemen laut MEDLINE: Breast Neoplasms, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Phosphoinositide-3 Kinase Inhibitors. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphoinositide-3 Kinase InhibitorsHumansFemaleMTOR InhibitorsProtein Kinase InhibitorsReceptors, EstrogenSignal TransductionAntineoplastic Agents

Stichwörter der Autor:innen

AKT inhibitorHormone receptor-positive breast cancerPI3K inhibitorPI3K/AKT/mTOR pathwayPrecision therapyTreatment

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphoinositide-3 Kinase InhibitorsMTOR protein, humanMTOR InhibitorsProtein Kinase InhibitorsReceptors, EstrogenAntineoplastic Agents

Autor:innen und Institutionen

  • Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; Tianjin Cancer Hospital Airport Hospital, Tianjin, China; National Clinical Research Center for Cancer, Tianjin, China. Electronic address: haoch…
  • Peking University Health Science Center, Beijing, China.
  • Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
  • Tianjin Cancer Hospital Airport Hospital, Tianjin, China.

Förderung

  • AstraZeneca

Zitieren

APA

Hao, C., Wei, Y., Meng, W., Zhang, J., & Yang, X. (2025). PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treatment Reviews, 132, 102861. https://doi.org/10.1016/j.ctrv.2024.102861

Vancouver

Hao C, Wei Y, Meng W, Zhang J, Yang X. PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer. Cancer Treatment Reviews. 2025;132:102861. doi:10.1016/j.ctrv.2024.102861

BibTeX
@article{Hao2025,
  author = {Hao, Chunfang and Wei, Yunchu and Meng, Wenjing and Zhang, Jie and Yang, Xiaonan},
  title = {PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer},
  journal = {Cancer Treatment Reviews},
  year = {2025},
  volume = {132},
  pages = {102861},
  doi = {10.1016/j.ctrv.2024.102861}
}
Kostenlos starten →